BY MARKETWIRE
-
Pfizer upgrades – has top line growth for the first time in over a year
The upward adjustment is made in reference to Pfizer’s second quarter report.
-
Roche speeds up within obesity
Roche reveals faster-than-expected weight problems drug launch, probably in 2028, and the Swiss acquisition of Carmot Therapeutics may carry as many as seven new drug candidates wi…
-
Philips on the rise: New orders increase for the first time in two years
CEO Roy Jakobs expects enhancements within the Chinese language market within the second half of 2024 after Philips was negatively affected by a significant Chinese language health…
-
Novo Nordisk may be on its way with an upward adjustment, Sydbank believes
The newest forecast from Novo Nordisk is for gross sales progress of 19-27% and working revenue progress of 22-30% – each in native forex.
-
GSK drops as weak vaccine sales eclipse raised forecast
Whereas GSK is experiencing challenges with gross sales of the Arexvy vaccine, there are optimistic tendencies and development in gross sales of medicine for HIV, most cancers and …
-
Lundbeck and Takeda slim down US collaboration agreement to royalties-only
The brand new collaboration mannequin will take impact from January 1, 2025. It entails that Lundbeck will stop all advertising and marketing efforts within the US for the antidepr…
-
Bad news for GN and Demant: Italian retail chain disappoints in the second quarter
Particularly, the European market, Amplifon’s largest, was worse than anticipated, whereas the US market was barely higher than analysts’ estimates.
-
Eli Lilly’s weight-loss blockbuster shows promise in slashing heart failure rate
The firm intends to send outcomes to regulatory authorities in the United States, looking for to increase Zepbound’s tag.
-
Demant corrects 2023 figures in connection with strategic review of Communications
Both Communications and Hearing Implants are currently fixed to be stopped procedures in Demant’s monetary declarations.
-
Smith & Nephew has low single-digit growth in the second quarter in wound care
Smith & Nephew’s operating earnings in the very first fifty percent of the year was a little over experts’ assumptions.